Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q92902

UPID:
HPS1_HUMAN

ALTERNATIVE NAMES:
Hermansky-Pudlak syndrome 1 protein

ALTERNATIVE UPACC:
Q92902; A8MRT2; O15402; O15502; Q5TAA3; Q8WXE5

BACKGROUND:
HPS1, integral to the BLOC-3 complex, acts as a guanine exchange factor, crucial for activating RAB32 and RAB38. This activation is essential for melanosome biogenesis and melanin production, processes vital for pigmentation. The protein's role underscores its importance in cellular function and its potential as a therapeutic target.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of BLOC-3 complex member HPS1 could open doors to potential therapeutic strategies for Hermansky-Pudlak syndrome 1. Given the protein's involvement in this genetically heterogeneous disorder, which leads to significant morbidity and mortality, targeting HPS1 offers a promising avenue for developing novel treatments.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.